Roche announced the CE-IVD launch of its automated digital pathology algorithm, the uPath PD-L1 (SP263) image analysis for non-small cell lung cancer (NSCLC). The algorithm provides pathologists with automated assessments of scanned slide images, according to a company press release.
Validated on the VENTANA PD-L1 (SP263) assay, the algorithm is integrated within the Roche uPath enterprise software, a digital platform for case management, collaboration, and reporting. This algorithm will help pathologists quickly determine whether tumors are positive for the PD-L1 biomarker, highlighting positively and negatively stained tumor cells with a clear visual overlay for easy reference.
Patients with tumors that are positive for the PD-L1 biomarker may be eligible for targeted treatment.
The launch of uPath PD-L1 (SP263) image analysis for non-small cell lung cancer follows the January 2019 release of the Roche uPath enterprise software. All algorithms in the suite for uPath software will provide image analysis of VENTANA DP 200 scanned slide images stained with a Roche tissue assay.
